Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 774 adults with plaque psoriasis across three groups: 156 people received a placebo (inactive treatment) for the first 16 weeks before switching to the study drug JNJ-77242113 200 mg; 311 people received JNJ-77242113 200 mg from the start; and 307 people received an already-approved medicine called deucravacitinib 6 mg. The trial was primarily measuring how many participants showed a meaningful improvement in their skin at 16 weeks, using two standard psoriasis scoring tools — one rated by a doctor (the IGA scale) and one that measures how much of the body is affected and how severe the patches are (the PASI scale). It is worth noting that the reported outcome data only compared the placebo group and the JNJ-77242113 group; figures for the deucravacitinib group were not included in the submitted results data. The reported data shows that, at 16 weeks, 68.5% of participants who received JNJ-77242113 from the start reached a doctor-assessed skin score of "clear" or "almost clear" (IGA 0 or 1), compared with 10.9% in the placebo group. On the PASI scale, 55.0% of the JNJ-77242113 group achieved at least a 90% reduction in their psoriasis score from where they started, versus 3.8% in the placebo group. For complete clearance of the skin score (PASI 100), the reported figures were 31.2% for JNJ-77242113 and 1.3% for placebo. Earlier in the trial, at week 4, the reported data shows 12.2% of the JNJ-77242113 group had reached a 75% improvement in their PASI score, rising to 74.3% by week 16, compared with 2.6% and 11.5% respectively for the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40976249) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the start of the study
- At least 10% of your body surface area is affected by psoriasis at both the screening and start of the study
- Your psoriasis scores at least 12 on a standard severity scale (called PASI) at both the screening and start of the study
- A doctor has rated your psoriasis as moderately severe or worse (a score of 3 or higher on a standard scale) at both the screening and start of the study
- Your doctor considers you a suitable candidate for light therapy or systemic (whole-body) medication to treat your plaque psoriasis
Who may not be able to join:
- You have a type of psoriasis other than plaque psoriasis, such as the widespread reddening type, the drop-shaped type, or the pus-filled blister type
- Your psoriasis was triggered or made worse by a medication you are currently taking, such as beta blockers, calcium channel blockers, or lithium
- You currently have, or show signs of, a serious, worsening, or poorly controlled condition affecting your kidneys, liver, heart, blood vessels, lungs, digestive system, hormones, nervous system, blood, joints, mental health, or metabolism
- You have a known allergy or intolerance to any of the study medications (JNJ-77242113 or deucravacitinib) or any of their ingredients
- You have had a major surgical procedure requiring general anesthesia within the 8 weeks before screening, have not fully recovered from surgery, or are planning to have surgery during the study period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinicaltrial, Janssen Research & Development, LLC
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16; Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.